U.S. market Closed. Opens in 9 hours 16 minutes

XLO | Xilio Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue1.90M1.85M1.50M1.06M240.00K
Gross Profit-1.90M-1.85M-1.50M-1.06M-240.00K
Operating Expenses75.70M89.15M75.04M54.56M19.03M
Selling, General & Admin27.00M29.95M23.86M10.65M4.77M
Research & Development52.14M59.20M51.19M43.91M14.26M
Other Operating ExpensesN/A927.00K-756.00K-656.00K1.72M
Operating Income-79.13M-89.15M-75.04M-54.56M-19.03M
Other Expenses / Income2.73M927.00K-756.00K-656.00K1.72M
Before Tax Income-76.40M-88.22M-75.80M-55.22M-17.31M
Income Tax ExpensesN/A-927.00K-1.50M858.70K68.14K
Net Income-76.40M-87.30M-74.30M-55.22M-17.31M
Interest ExpensesN/A-927.00K600.00K600.00KN/A
Basic Shares Outstanding27.50M27.39M27.36M27.47M27.47M
Diluted Shares Outstanding27.50M27.39M27.36M27.47M27.47M
EBITDA-77.23M-89.15M-75.04M-53.50M-18.79M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-76.40M-89.15M-75.20M-53.76M-17.24M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙